Drug intelligence / Profile preview

STAT1 siRNA

Development stage
Preclinical
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous, Intratumoral, Inhalation
01

Overview

STAT1 siRNA is a small interfering RNA designed to silence the expression of the Signal Transducer and Activator of Transcription 1 (STAT1) protein. In the context of sickle cell disease (SCD) research, STAT1 has been identified as a recruitment partner for 8-Oxoguanine DNA Glycosylase 1 (OGG1) in promoting inflammatory responses. By utilizing STAT1 siRNA to knock down STAT1 levels in macrophages, researchers have demonstrated a significant reduction in the expression of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α. This suggests that targeting the STAT1 pathway may be a potential therapeutic strategy for managing inflammation in SCD.

Other names
STAT1-unique siRNAsSTAT-1-unique siRNAsSTAT 1-unique siRNAssiRNA targeting STAT1
02

Targets

STAT1 (Signal transducer and activator of transcription protein 1)

Beyond the preview

Go deeper on STAT1 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on STAT1 siRNA.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call